Abstract 1666P
Background
Substance use and mental health disorders significantly contribute to disparities in cancer care, particularly in urban underserved areas like the South Bronx, characterized by a substantial Latinx and Black population. This study aimed to evaluate the influence of substance use and mental illness on cancer care among newly diagnosed patients at the Lincoln Cancer Center.
Methods
A retrospective analysis was conducted on newly diagnosed cancer patients treated between January and August 2022. Various aspects of their cancer care journey were assessed, including delays in diagnosis, treatment selection, compliance with care, incidence of unscheduled emergency department/inpatient visits, rates of follow-up loss, and mortality. Substance use and mental health disorders were evaluated through electronic health record reviews and structured telephone interviews. Statistical analysis was performed using descriptive statistics and the independent samples T-test in SPSS. This study was approved by the Institutional Review Board at our hospital.
Results
The study included 208 patients, with 106 (51%) having substance use disorders, 41 (19.1%) with mental health disorders and 31 (14.9%) having both. Among patients with mental health disorders, 34% received medication and 12% had regular psychiatric care. Patients with mental health disorders but no substance use, tended to be diagnosed at later cancer stages (50% vs 41.3% at stage 4). Patient with either mental health disorders or substance use disorder has delayed cancer diagnosis from initial suspicion date (64.09 days vs 46.71 days, p = 0.154) and higher non-compliance to clinic visits (20.9% vs 14.0%, p=0.015) and higher ED visit (1.67 vs 1.27, p = 0.71), admission rate (0.98 vs 0.57, p=0.232) and mortality compared to those without, showing odds ratios of 1.203 [95% CI 0.50-2.89] although statistically insignificant due to the small sample size.
Conclusions
Patients with either mental health disorders or substance use disorder exhibited more diagnostic delays, higher non-compliance with their cancer care journey, increased ED/inpatient visits, and mortality rates. Addressing both physical and mental health is crucial for narrowing cancer disparities in this vulnerable population.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1699P - Impact of Latino ethnicity on the gut microbiome and response to immune checkpoint inhibition (ICI) with CBM588 in patients (pts) with metastatic renal cell cancer (mRCC)
Presenter: Regina Barragan-Carrillo
Session: Poster session 11
1700P - Impact of sarcomatoid (S) and rhabdoid (R) components (comp.) on the efficacy of nivolumab (N) +/- ipilimumab (I) in the first-line (L1) treatment of metastatic clear cell renal cell carcinoma (mRCC) in the randomized phase II BIONIKK trial
Presenter: Yann-Alexandre Vano
Session: Poster session 11
1701P - NEOTAX: A phase II trial of neoadjuvant toripalimab plus axitinib for clear cell renal cell carcinoma with inferior vena cava tumor thrombus
Presenter: Liangyou Gu
Session: Poster session 11
1702P - Updated results of phase II study of cabozantinib (Cabo) with nivolumab (Nivo) and ipilimumab (Ipi) in advanced renal cell carcinoma with divergent histologies (RCCdh)
Presenter: Bradley McGregor
Session: Poster session 11
1703P - Updated overall survival in patients with prior checkpoint inhibitor (CPI) therapy in the phase III TIVO-3 study
Presenter: Miguel Zugman
Session: Poster session 11
1704P - Potential surrogate endpoints for overall survival (OS) in immunotherapy (IO)-treated metastatic renal cell carcinoma (mRCC): An International Metastatic Database Consortium (IMDC) study
Presenter: Renee Saliby
Session: Poster session 11
1705P - Association between baseline radiological tumor burden (BRTB) and outcomes in metastatic clear cell renal cell carcinoma (mccRCC) treated with first line (1L) immunotherapy (IO)-based regimens
Presenter: Rashad Nawfal
Session: Poster session 11
1707P - A plasma proteomic based algorithm is associated with prognosis in renal cell carcinoma
Presenter: Eddy Saad
Session: Poster session 11
1708P - The clinical value of tumor-informed minimal residual disease detection in renal cell carcinoma
Presenter: linhui wang
Session: Poster session 11